Clinical Trial

Ibd CAncer and seRious Infections in France (I-CARE 2)

Study acronym: I-CARE 2
Recruiting
View on ClinicalTrials.gov →
Summary
This is a French prospective longitudinal observational multicentre cohort study. Primary objective : to assess prospectively the presence and the extent of safety concerns (cancer, serious infections, arterial and venous thrombotic events) in patients with CD and UC and treated with JAKi, anti-IL23p19, and S1p modulators.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-13.
Status change: Not Yet Recruiting → Recruiting 2025-03-12
Trial Details
NCT Number NCT06089590
Lead Sponsor Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Collaborators: Sanoia
Conditions IBD, Ulcerative Colitis, Crohn Disease
Enrollment 6,000 participants
Start Date 2024-01-25
Primary Completion 2031-03-01 (estimated)
Study Completion 2031-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-14